Emphasis on Dosage Form (Injectables, Tablets, Transdermal Patches, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others); and Region/Country
Global Scopolamine Market was valued at more than USD 400 million in 2020 and is expected to grow at a significant rate of around 5% during the forecast period. The global scopolamine market is anticipated to witness an uptick owing to the rising number of people having motion sickness, and growing awareness among the population globally. About 1 in 3 people are considered highly susceptible to motion sickness. Furthermore, American Institute of Stress, 80% of U.S. workers said that they experience stress on the job. Also, Over three-quarters of adult report symptoms of stress, including headache, tiredness, or sleeping problems, as per the American Psychological Association, 2019. This rising number of people having psychological stress is also one of the prominent factors due to which people feel motion sickness which in turn is also increasing the demand for scopolamine drugs among the population. In addition to this, the growing number of travelers across the globe and an increasing number of surgeries due to chronic diseases are also some of the factors contributing to the growth of the market.
Pfizer Inc., Baxter International Inc., Myungmoon Pharm Co Ltd., Novartis AG, Perrigo Company PLC, Fine Chemicals Corporation, GSK plc, Alchem International Pvt. Ltd., Phytex Australia Pty Ltd., Caleb Pharmaceuticals, Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with scopolamine.
Insights Presented in the Report
“Amongst dosage form, transdermal patches category to witness higher CAGR during the forecast period”
Based on dosage form, the scopolamine market is segmented into injectables, tablets, transdermal patches, and others. The transdermal patches scopolamine segment accounted for a significant market share in 2020 and it is estimated that it will grow rapidly during the projected timeframe as they are widely for the treatment of motion sickness nowadays. Furthermore, growth in the number of domestic and international travelers and in areas of product launches in the market is also positively influencing the growth of the market.
“Amongst distribution channel, the hospital pharmacies to hold a significant share in the market in 2020”
On the basis of distribution channels, the market is fragmented into hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies to hold a significant share in the market in 2020. This is mainly due to the increasing preference of the patients to avail treatment in hospitals and the easy availability of the medication in hospital pharmacies. However, the online pharmacy segment is expected to witness significant growth owing to the growing penetration of e-pharmacy platforms across the world coupled with increasing awareness regarding services offered by e-pharmacy.
“North America to hold a significant share in the market”
For a better understanding of the market adoption of the All-Terrain Vehicle industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. The major factors such as well-established healthcare infrastructure, a rising number of surgeries, and an increasing number of travelers in the region. For instance, U.S. domestic travel increased 1.7% in 2019 to a total of 2.3 billion person-trips. Also, Leisure travel accounted for 80% of all U.S. domestic travel in 2019. Furthermore, the presence of key industry players in the region and an increasing number of product launches are also some of the factors contributing to the market growth.
Reasons to buy this report:
Customization Options:
The global scopolamine market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology Or Assumption
3. Market Synopsis
4. Executive Summary
5. Impact Of Covid-19 On The Scopolamine Market
6. Scopolamine Market Revenue, 2020-2028f
7. Market Insights By Dosage Form
8. Market Insights By Distribution Channel
9. Market Insights By Region
10. Scopolamine Market Dynamics
11. Scopolamine Market Opportunities
12. Scopolamine Market Trends
13. Demand And Supply-side Analysis
14. Value Chain Analysis
15. Competitive Scenario
16. Company Profiled
17. Disclaimer
Research Methodology for the Scopolamine Market Analysis (2022-2028)
Analyzing the historical market, estimating the current market, and forecasting the future market of the global scopolamine market were the three major steps undertaken to create and analyze the adoption of scopolamine in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global scopolamine market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the scopolamine market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the scopolamine market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as dosage form and distribution channel. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the scopolamine market. Further, we conducted factor analysis using dependent and independent variables such as various dosage form and distribution channel of scopolamine. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the scopolamine market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global scopolamine market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2028 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global scopolamine market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of dosage form and distribution channel in the global scopolamine market.
The main objective of the Global Scopolamine Market Study
The current & future market trends of the global scopolamine market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
